Antibiotic Development Needs Economic Incentives

  02 March 2021

The antibiotic market is categorically different from that of other pharmaceuticals. Research and development of any drug is expensive, but antibiotics have comparatively low prices and sales volume.

As a result, the companies making them are going bankrupt, and many potentially lifesaving drugs end up falling into an antibiotic valley of death—dropping out of production before they can reach patients.

 

Further reading: PEW
Author(s): Wes Kim
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Your Biweekly Source for Global AMR Insights!

Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.

Don’t miss out on staying ahead in the global AMR movement—subscribe now!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed